ALL-MSCs express higher levels of SNAT5 transporter and secrete more Asn than HD-MSCs. (A) Fractional Asn efflux (Equation 3, supplemental Materials and Methods) was determined in ALL-MSCs and HD-MSCs. Data are means ± SD of 15 independent experiments performed with MSCs from 3 different patients (UPN#12-13-16, supplemental Table 2A) or healthy donors (UPN#9-10-11, supplemental Table 2B). *P < .05. (B) The expression of the indicated genes was determined in a panel of ALL-MSCs and HD-MSCs. Data are expressed as fold-change, normalizing against the average expression of healthy donors and are means ± SD of 6 independent experiments performed with MSCs from 6 different patients (UPN#11-12-13-14-15-16, supplemental Table 2A) or healthy donors (UPN#9-10-11-12-13-14, supplemental Table 2B). *P < .05; **P < .01 (C) Western blot of SNAT5 expression in 2 panels of MSCs obtained from 4 distinct ALL patients (UPN#11-14-15-16, supplemental Table 2A) or healthy donors (UPN#10-11-12-13, supplemental Table 2B) (top). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for loading control. Densitometric analysis of SNAT5 expression, normalized for GAPDH (bottom). Means ± SD are shown. *P < .05. (D) The mean intensity of SNAT5 signal was detected in ALL-MSCs derived from 3 different patients (UPN#11-12-14, supplemental Table 2A), and HD-MSCs derived from 3 different donors (UPN#9-11-13, supplemental Table 2B). Data are expressed as the ratio between mean intensity and the number of cells in the same fields (81 in 10 fields for ALL-MSCs and 93 in 19 fields for HD-MSCs) ***P < .001. For all the panels, Mann-Whitney U test was used. For panels A, B, C, and D, in each panel different symbol identifies MSCs from an individual donor.